SUDA Pharmaceuticals Ltd. announced the appointment of Professor Gunnar Birgegård to its Scientific Advisory Board. SUDA is developing anagrelide to be used as an adjunct therapy to treat patients with specific solid tumours and thrombocytosis (elevated platelets). The appointment represents another strong addition to the anagrelide programme. Professor Gunnar Birgegård is professor of Haematology at Uppsala University, Uppsala, Sweden. His early research interests focused on iron metabolism and inflammation as well as erythropoietin pathophysiology, especially in polycythaemia vera. His research has included work on erythropoiesis and iron, mainly with regards to ferritin and inflammation, and his group was one of the first to publish a radioimmunoassay method for measuring serum erythropoietin. Professor Birgegård has also been involved in implementing erythropoietin treatment studies in autotransfusion and cancer as well as intravenous iron and Epo efficacy.